At a glance
- Originator Uriach
- Class Antifungals
- Mechanism of Action Cell wall inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 17 Dec 1997 Discontinued-I for Mycoses in Spain (PO)
- 19 Nov 1996 Phase-I clinical trials for Mycoses in Spain (PO)
- 01 Jun 1995 New profile